NRx Pharmaceuticals, Inc. (NRXP)
NASDAQ: NRXP · Real-Time Price · USD
2.370
+0.190 (8.72%)
At close: Dec 19, 2025, 4:00 PM EST
2.351
-0.019 (-0.80%)
After-hours: Dec 19, 2025, 7:58 PM EST
NRx Pharmaceuticals Stock Forecast
Stock Price Forecast
The 6 analysts that cover NRx Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $30.5, which forecasts a 1,186.92% increase in the stock price over the next year. The lowest target is $18 and the highest is $47.
Price Target: $30.5 (+1,186.92%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for NRx Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 5 | 6 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 5 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $40 | Strong Buy | Reiterates | $40 | +1,587.76% | Dec 16, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $34 | Strong Buy | Maintains | $34 | +1,334.60% | Dec 3, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $25 | Strong Buy | Reiterates | $25 | +954.85% | Dec 3, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $34 | Strong Buy | Maintains | $34 | +1,334.60% | Dec 2, 2025 |
| D. Boral Capital | D. Boral Capital | Strong Buy Maintains $34 | Strong Buy | Maintains | $34 | +1,334.60% | Nov 17, 2025 |
Financial Forecast
Revenue This Year
19.04M
Revenue Next Year
141.58M
from 19.04M
Increased by 643.59%
EPS This Year
-0.79
from -2.36
EPS Next Year
1.40
from -0.79
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 22.9M | 253.5M | ||||
| Avg | 19.0M | 141.6M | ||||
| Low | 16.4M | 41.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | 1,231.3% | ||||
| Avg | - | 643.6% | ||||
| Low | - | 119.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -0.60 | 2.45 | ||||
| Avg | -0.79 | 1.40 | ||||
| Low | -0.95 | 0.41 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.